Rapamycin ameliorates IgA nephropathy via cell cycle-dependent mechanisms

Area of Science:

• Nephrology
• Cell Biology
• Pharmacology

Background:

• Immunoglobulin A (IgA) nephropathy is the leading cause of glomerulonephritis globally.
• Cell cycle regulation's role in IgA nephropathy pathogenesis is under investigation.
• Understanding therapeutic targets is crucial for managing this kidney disease.

Purpose of the Study:

• To investigate if rapamycin ameliorates IgA nephropathy through cell cycle-dependent mechanisms.
• To assess rapamycin's impact on mesangial cell proliferation and kidney function in an IgA nephropathy model.

Main Methods:

• Established an IgA nephropathy rat model and treated with rapamycin.
• Measured 24-h urinary protein, renal function, and IgA deposition.
• Assayed cell proliferation (PCNA), cell cycle (flow cytometry), and protein expression (Western blotting) in rat mesangial cells.

Main Results:

• Rapamycin reduced proteinuria, preserved kidney function, and decreased IgA deposition.
• Rapamycin inhibited mesangial cell proliferation and induced G1 phase cell cycle arrest.
• Rapamycin upregulated p27(Kip1) via AKT/mTOR signaling, without altering cyclin E or CDK2 levels.

Conclusions:

• Rapamycin demonstrates therapeutic potential in IgA nephropathy by modulating cell cycle regulation.
• Inhibition of mesangial cell proliferation and subsequent reduction in IgA deposition contribute to rapamycin's protective effects.
• Targeting cell cycle mechanisms offers a promising strategy for slowing IgA nephropathy progression.